Business
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France, July 28, 2025--MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Oncology
About this update from Maat Pharma
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":442,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/335af44e87cae48327cfd7282e021592"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i0gJkviqKKzK9LOXKDKARA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc2NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/335af44e87cae48327cfd7282e021592","width":442,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Tranche-based financing to support clinical development for the Company’s late-stage assets in hemato-oncology including Xervyteg® currently under review for potential approval by the EMA and MaaT033 currently in Phase 2b clinical evaluation","length":241,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Funding is part of the European Investment Bank (EIB)’s strategy to support biotech companies with cutting-edge expertise in therapeutic areas such as hemato-oncology","length":166,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Structured Debt financing from the EIB is another stepping stone in MaaT Pharma’s multi-sourcing financing strategy","length":115,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":522,"olType":false},{"type":"text","content":"LYON, France, July 28, 2025--(BUSINESS WIRE)--Regulatory News:","length":62,"tagName":"p"},{"type":"text","content":"MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants.","length":865,"tagName":"p"},{"ty...